Refine by
Tumor Mutation Equipment Supplied In Europe
10 equipment items found
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor Origin (TO), ...
by:Evaxion Biotech A/S based inHørsholm, DENMARK
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune ...
Manufactured by:Singleron Biotechnologies GmbH based inKöln, GERMANY
FocuSCOPE is a high-throughput single cell multi-omics sequencing solution that can detect both genetic variants and transcriptome from the same single cells. Thus, FocuSCOPE® provided a tool to decipher the connection between genotype and phenotype at single cell ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC restricted and not ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Tempus xE (version 2) is a whole exome next-generation sequencing assay that analyzes the entire coding region (exome) of the patient’s genome, combined with whole transcriptome RNA sequencing. Clinical sequencing is performed to 500x depth of coverage for tumor specimens and 150x for normal specimens for the clinically enhanced regions (648 genes). Non-enhanced regions are performed at ...
Manufactured by:Sysmex Partec GmbH based inGoerlitz, GERMANY
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The ...
Manufactured by:Molecular Devices, LLC. based inSan Jose, CALIFORNIA (USA)
Organoids are derived from biopsies and tissues sampled from patients or subjects (usually termed Patient-Derived Organoids, or PDOs). PDOs are self-organising cell structures that mimic the tissue or organ from which they are derived – they are often termed ‘mini-organs’. ...
Manufactured by:Therawis based inMunich, GERMANY
Oncosome.HER2 is a liquid biopsy diagnostic for the detection of HER2 in blood to identify patients eligible for HER2 targeted therapy. Oncosome.HER2 would address an high unmet medical ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint ...